CORC Video & Slide Archive for 2020-21

Instructions

Monday, September 21, 2020, 12:00 AM - Sunday, October 31, 2021, 12:00 AM

AMA PRA Category 1 Credits™ (36.75 hours), Non-Physician (36.75 hours)

Due to COVID-19, this year the course will be offered virtually as a library of pre-recorded videos. Registered participants will be provided with login details to access the videos and course material at their own pace. The course will be available online starting September 21, 2020.

This educational program will cover data supporting guidelines, recommendations, and recent advances regarding therapeutic options for patients with solid tumors and malignant and benign hematologic disorders. On completing this program, learners will have a deeper understanding of the pathogenesis, diagnostic evaluation, and therapeutic modalities available for a breadth of solid tumors and hematologic disorders. Learners will also be provided with course material and self-assessment for CME and MOC credits.

METHOD OF PARTICIPATION

In order to complete this training, access to the internet and a computer is required. You must receive a minimum passing score of 80% on the post-test (max. 3 attempts) in order to receive your CME credit. Each module will have a required pre-test, educational component, and post-test. 

DATE

Date of Original Release: September 21, 2020

Termination Date: October 30, 2021

Registration will close for this online education on June 30, 2021. Users have until the accreditation term ends on October 30, 2021 to complete the selected module(s).

POST-TEST/EVALUATION

In order to receive CME credit, an 80% pass rate is required. If after three (3) attempts you are unsuccessful, you will be ineligible to receive CME credit for the module. However, content will always be available to you. It is important to know that once you have started the Post-Test (Examination), if you exit the Post-Test without responding to all questions, it will be counted as a failed attempt. Only three (3) attempts are permitted.

TECHNICAL REQUIREMENTS

Minimum browser requirements for successful access and completion for this activity are as follows:

Chrome version 70.0 or newer | Firefox version 63.0 or newer 

FACULTY & DISCLOSURES

The following course planners have disclosed the following:

• Andrew Coveler, MD (Course Co-Chair/Planner/Reviewer/Speaker): no relevant financial relationships to disclose
• Ryan Cassaday, MD (Course Co-Chair/Planner/Reviewer/Speaker): Honoraria/Consulting/Teaching: Amgen, Pfizer; Grant/Research Support: Amgen, Merck, Kite/Gilead, Pfizer, Vanda Pharmaceuticals; Major Stock Shareholder: Seattle Genetics
• David Zhen, MD (Course Reviewer/Speaker): no relevant financial relationships to disclose

Speaker disclosures can be viewed by clicking here.

1. Define the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common malignant hematological diseases.
2. Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common solid tumor malignancies.
3. Integrate guideline-based treatments into clinical practice while personalizing care appropriately for the patient.
4. Incorporate new therapeutic and diagnostic approaches into clinical practice as appropriate.

 

	Certificate Fee
All Learners	$25.00 per module

The fee for this course includes access to online materials and transcript of AMA PRA Category 1 Credits™ and MOC.

 

Enduring Material Content

COPYRIGHT
The content is the property of the University of Washington and is protected by law, including but not limited to copyright and trademark statutes. This content is for educational purposes only and may not be used for commercial gain. The University of Washington reserves the right to revise or withdraw content from use. Redistribution of this content is strictly prohibited. 
For questions related to content use, please contact the CME office at [email protected].

INSTRUCTIONS

• To access to the content, click the hyperlink below for the education module you want to purchase.
• Register for the education module, then continue with these instructions.
• You must complete the pre-test first in order to access the video.
• After completing the video, you must complete the post-test.
• Upon successful completion of the post-test, you will be asked to complete the evaluation. Your CME certificate will be automatically generated after you submit the evaluation.
• Alternatively, you can access the evaluation at a later time. To access the evaluation at a later time, go to "MyCME" and select "Evaluations & Certificates." Complete the required evaluation. Your certificate can also be located here after the evaluation has been submitted.

 

Section I	Thoracic, Head and Neck Oncology
EN2105MM	NSCLC - Adjuvant/Locally Advanced by Rafael Santana-Davila, MD
EN2105GG	Metastatic Non-Small Cell Lung Cancer by Christina Baik, MD, MPH
EN2105MO	Small Cell Lung Cancer: The Basics by Rafael Santana-Davila, MD
EN2105DD	Head and Neck Cancer by Cristina Rodriguez, MD
EN2105W	Malignant Pleural Mesothelioma by Bernardo Goulart, MD, MS
Section II	Breast Oncology
EN2105VV	Therapy for Non-Invasive Breast Cancer and Prevention by Rachel Yung, MD
EN2105BB	Adjuvant Therapy for Breast Cancer by William Gwin, MD
EN2105AA	Metastatic Breast Cancer by Natasha Hunter, MD
Section III	GI Oncology
EN2105LL	Esophageal and Gastric Cancer by Veena Shankaran, MD, MS
EN2105FF	Biliary Tract Cancers by David Zhen, MD
EN2105TT	Hepatocellular Carcinoma by William P. Harris, MD
EN2105RR	Pancreas Cancer by Gabriela Chiorean, MD
EN2105NN	Colorectal Cancer - Adjuvant by Stacey Cohen, MD
EN2105NO	Colorectal Cancer - Metastatic by Stacey Cohen, MD
EN2105Y	Anal Cancer by Andrew Coveler, MD
EN2105EE	Gastroenteropancreatic Neuroendocrine Tumors by Kaylyn Kit Man Wong, MD
Section IV	GU Oncology
EN2105SS	Prostate Cancer by Tanya Dorff, MD
EN2105QQ	Testicular Cancer by Todd Yezefski, MD
EN2105UU	Systemic Therapy in the Treatment of Bladder Cancer by Michael Schweizer, MD
Section V	Gynecologic Oncology
EN2105CC	Endometrial and Cervical Cancers by Kathryn Pennington, MD
EN2105OO	Updates in Ovarian Cancer by Renata R. Urban, MD
Section VI	Other Malignancies: Renal, Melanoma, CNS, Sarcoma
EN2105JJ	CNS Cancers by Vyshak Venur, MD
EN2105KK	Renal Cell Carcinoma by Scott Tykodi, MD, PhD
EN2105II	Sarcoma Board Review 2020 by Seth Pollack, MD
EN2105X	Melanoma and Other Skin Cancers by Shailender Bhatia, MD
Section VII	Lymphomas
EN2105C	Indolent Non-Hodgkin Lymphoma: 2020 by Solomon Graf, MD
EN2105L	Aggressive B-Cell Non-Hodgkin Lymphomas by Stephen Smith, MD
EN2105E	Hodgkin Lymphoma by Ryan Lynch, MD
EN2105V	Peripheral T-Cell Lymphomas by Andrei Shustov, MD
Section VIII	Leukemia and Myelomas
EN2105K	Acute Myeloid Leukemia in 2020 by Mary-Beth Percival, MD
EN2105A	Acute Lymphoblastic Leukemia in Adults by Ryan Cassaday, MD
EN2105J	Chronic Myeloid Leukemia in 2020 by Vivian Oehler, MD
EN2105F	Chronic Lymphocytic Leukemia and Hairy Cell Leukemia by Mazyar Shadman, MD, MPH
EN2105H	Monoclonal Gammopathies and Multiple Myeloma by Edward Libby, MD
EN2105B	Management of Multiple Myeloma: Board Review by Andrew Cowan, MD
Section IX	Hematology
EN2105S	Inherited and Acquired Marrow Failure by Sioban Keel, MD
EN2105I	Benign White Cell Disorders by Michael Linenberger, MD
EN2105G	Myeleoproliferative Neoplasms by Anna Halpern, MD
EN2105N	The Myelodysplastic Syndromes by Aaron T. Gerds, MD, MS
EN2105M	Iron Metabolism Disorders and Hemolytic Anemias by Kleber Fertrin MD, PhD
EN2105P	Hemoglobin Disorders by Kleber Fertrin, MD, PhD
EN2105O	Thrombotic Microangiopathies (TTP/HUS) by Allyson Pishko, MD, MSCE
EN2105R	Thrombocytopenia: Updated Review by Terry Gernsheimer, MD
EN2105T	Bleeding Disorders by Rebecca Kruse-Jarres, MD, MPH
EN2105U	Hematopoietic Stem Cell Transplantation by Rachel Salit, MD
EN2105D	Transfusion Medicine by Jill Johnsen, MD
EN2105Q	Update in Venous Thromboembolism by David Garcia, MD
Section X	Other Topics: Pharmacology I and II, ID Complications, Integrative Medicine, Hereditary Cancer Syndromes, and   Radiation Oncology
EN2105WW	Supportive Care by Keith Eaton, MD, PhD
EN2105XX	Integrative Oncology - What Oncology Clinicians Need to Know by Heather Greenlee, ND, PhD, MPH
EN2105HH	Hereditary Cancer Syndromes by Cynthia Handford, MSc, LCGC
EN2105ZZ	Infections in Cancer and HCT Recipients by Steven Pergam, MD, MPH
EN2105Z	Cancer Pharmacology I by Zakary Cerminara, PharmD, BCOP
EN2105YY	Cancer Pharmacology II by Amy Indorf, PharmD, BCOP
EN2105PP	General Principles of Radiation Oncology by Jonathan Chen, MD, PhD

      

Accreditation with Commendation: The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

No faculty are available for this activity at this time.